key: cord-0943391-gis81xgq
authors: George, Saira; Muhaj, Fiorinda F.; Nguyen, Celine D.; Tyring, Stephen K.
title: Part I Antimicrobial resistance: Bacterial pathogens of dermatologic significance and implications of rising resistance
date: 2022-02-02
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2021.11.066
sha: 5fd01f5e94ef04f675bd53397e2349777d1f6a87
doc_id: 943391
cord_uid: gis81xgq

Although the coronavirus pandemic has been the defining global health crisis of our time, public health officials have been sounding the alarm of another ominous threat for years: an impending antimicrobial resistance (AMR) crisis. Antibiotics in dermatology are often used for prolonged courses in the treatment of skin and soft tissue infections and common inflammatory skin conditions, increasing the risk of microbiome alteration and antibiotic-related adverse effects, all while exerting consequential selective pressures on both pathogenic and bystander bacteria. In this review, we hope to raise awareness of the crisis of AMR and review the resistance concerns related to dermatology-relevant bacterial pathogens.

One of the greatest global public health threats of the 21st century is growing antimicrobial resistance (AMR). Concerns for a looming AMR crisis may have been temporarily 48 overshadowed by the coronavirus pandemic, but many experts worry that pandemic-induced 49 increases in antibiotic exposures, hospitalizations, and diverted resources may have only 50 accelerated its arrival. 1-4 51

Since penicillin's discovery in 1928, antibiotic therapy has been a foundational pillar of 52 modern medicine. Unfortunately, the rate at which bacterial pathogens are becoming resistant 53 to currently available antibiotics has consistently outpaced the rate of new antibiotic 54 development. 5 The Centers for Disease Control (CDC) estimate that AMR infections already 55 cause 1 death every 15 minutes in the United States. 6 Worldwide, resistant pathogens account 56 for at least 700,000 deaths each year and are projected to cause 300 million deaths, making 57 AMR a top 3 public health concern of the 21st century. 7-8 Resistance among bacteria such as S. 58 aureus, S. pyogenes, and P. aeruginosa are among those that the CDC and WHO consider 59 prioritized threats. 6,8 60

The development of an AMR crisis, fueled largely by the overuse and misuse of 61

antibiotics, 9-13 should be a rallying call for increased antibiotic stewardship. The CDC estimate 62 that 50% of outpatient antibiotics are inappropriately prescribed based on agent selection, 63 dosing, or duration, 14 and at least 30% of outpatient antibiotics are given unnecessarily. 15 Livestock workers are at significantly higher risk for LA-MRSA colonization and subsequent 120 infection than the general population. 33 Currently, LA-MRSA accounts for 15% of community-121 acquired SSTIs and 1-2% of nosocomial infections; multidrug resistance is also observed in LA-122

MRSA. 21 As with other S. aureus strains, carriers are at risk of subsequent infection and serve as 123 important reservoirs for person-to-person transmission. 22 The emergence of LA-MRSA 124 highlights concerns about zoonotic transmission and the development of AMR from widespread 125 antibiotic use in animal husbandry. 126

The successful dissemination of MRSA poses significant challenges for the management 127 of skin and soft tissue infections [ Figure 1 ]. 34 Although CA-MRSA are sensitive to tetracyclines, 128 trimethoprim-sulfamethoxazole, and clindamycin, resistance to these agents has been reported 129 and antibiotic selection should be guided by susceptibility testing. 35 Clindamycin's oral 130 formulation and activity against both S. aureus and S. pyogenes make it useful for empiric 131 outpatient treatment of SSTIs. Clindamycin resistance occurs with the acquisition of 132 erythromycin-ribosomal-methylase, erm, a gene that encodes for the methylation of the 133 bacterial 23S ribosomal subunit, the shared action site of both macrolides and clindamycin. 26 134

The resulting cross-resistant phenotype, known as MLSb (macrolide-lincosamide-streptogramin 135 B), is seen in MRSA, MSSA, and S. pyogenes. 26 Streptococcus pyogenes (Group A Streptococcus (GAS)) is a gram-positive coccus that 150 causes a variety of infections and immune-mediated sequelae due to antigenic mimicry, 151 interactions with human immunity, and expression of virulence factors, 20,37-40 often with 152 prominent skin findings [ Table 2 ]. Asymptomatic carriage has been reported in 4-5 % of adults 153 and 2-20 % of children. 41 154 J o u r n a l P r e -p r o o f GAS most commonly causes pharyngitis and impetigo. 40 Invasive diseases, including 155 bacteremia, cellulitis, necrotizing fasciitis, pneumonia, and puerperal infections, carry a 156 mortality rate of 7-30% and can be complicated by progression to streptococcal toxic shock 157 syndrome (STSS) in one-third of the cases with an associated mortality of up to 81%. 39,40 158 Unlike S. aureus, GAS is universally sensitive to penicillin, which remains the treatment 159 of choice due to its efficacy, safety, narrow spectrum, and low cost. 37, 39, 40, 42 In invasive GAS 160 infections, however, penicillin monotherapy is associated with higher mortality 39 and the 161 addition of clindamycin is recommended. The high inoculum of invasive infection means a 162 bacterial stationary growth phase in which PBPs are relatively underexpressed is reached 163 quickly and makes penicillin, but not clindamycin, 37,39,40 less effective. Additionally, 164 clindamycin's ability to inhibit bacterial protein synthesis reduces the GAS toxin production 165 known to complicate invasive infections. 37,39,42 166

Since the 1980s, there has been an increase in the incidence and severity of invasive 167 GAS infections. 39,40 More than 20% of invasive GAS infections are due to clindamycin-and 168 erythromycin-resistant strains in the US. Increasing rates of resistance have also been reported 169 in Europe 43,44 and Asia, with as many as 94% of isolates in China demonstrating clindamycin 170 resistance. 45 The rise in clindamycin resistance can be partially attributed to soaring rates of 171 macrolide resistance over the last 40 years that have paralleled preferential use of macrolides 172 to treat localized GAS infections. 40,46-48 Since concomitant macrolide and clindamycin resistance 173 can arise through the acquisition of erm, the overuse of macrolides for localized GAS infections 174 also promotes clindamycin resistance and jeopardizes the ability of clindamycin to serve as an has been isolated from more than 80% of patients with clindamycin-resistant C. acnes 51,53 218 Furthermore, 35% of acne patients on antibiotics were found to carry oropharyngeal GAS, 85% 219 of which was tetracycline-resistant. 17 The use of clindamycin and doxycycline in acne therapy 220 can also select for resistant MRSA strains, limiting the use of these agents in MRSA infections. 53 221

Recent evidence suggests that even low-dose, or sub-antimicrobial doses of antibiotics like 222 doxycycline or minocycline may still potentiate resistance through a variety of mechanisms. 95-97 223

Novel narrow-spectrum antibiotics for acne may help limit resistance. Sarecycline, a 224 tetracyline antibiotic developed for the treatment of acne maintains high activity against gram-225 positive bacteria including C. acnes and demonstrates a low propensity for inducing resistance. Owing to intrinsic resistance mechanisms the available armamentarium against wild-244 type, P. aeruginosa includes only a few antibiotic classes [ Table 3 ]. 60-63 P. aeruginosa has 245 developed resistance mechanisms to all available anti-pseudomonas antibiotic classes, largely 246 due to the increased use of these agents coupled with efficient transmission of resistance 247 traits. 62 Since quinolones upregulate and serve as substrates for all four known pseudomonas 248 efflux systems, continuous quinolone exposure is an important risk factor for the generation of 249

The global rise in MDR P. aeruginosa, defined as resistance to one drug agent in at least Phage therapy. Phage therapy is a technology that utilizes bacterial viruses to 1) 285 selectively attack a bacterial population, 2) deliver drug molecules to a bacterial target, and 3) 286 insert enzymes that inactivate or reverse resistance genes. 72-75 Given their ubiquitous nature 287 and high specificity for bacterial receptors, bacteriophages can be engineered to target any 288 pathogenic bacterial population with no damage to collateral flora. 72,75 289

Phage therapy has been investigated in the management of ulcers, burns, and chronic 290 wounds (Table 5) . [76] [77] [78] [79] [80] [81] In addition to their specificity, efficacy against S. aureus and 291

Pseudomonas biofilms make bacteriophages an attractive modality in the management of 292 chronic wounds, ulcers, and acne. 75 C. acnes bacteriophages have shown in-vitro efficacy in 293 lysing C. acnes colonies without affecting collateral microbes, 73, 74 a significant advantage 294 compared to currently used antibacterials. Table 3 . Antipseudomonal antibiotics and mechanisms of resistance 601 Table 4 . Types of tuberculosis resistance and overview of treatment 602 

Binding to 16S rRNA within 30S ribosomal subunit → inhibition of protein synthesis 1) Active drug efflux via tetracycline efflux pumps encoded by plasmid-borne genes Tet (K) and Tet (L) 2) Ribosomal target protection via transposon-encoded genes tet (M) and tet (O) that catalyze tetracycline dissociation from the ribosome

Binding to 23S rRNA of 50S ribosomal subunit → inhibition of protein synthesis

Modification of drug-binding site via erm gene, an enzyme that methylates the 23S rRNA → variable cross-resistance to macrolides, lincosamides, and streptogramin B (MLSb phenotype)

Binding to D-ala-D-ala residues → inhibition of peptidoglycan cell wall synthesis VISA: inhibition of drug binding to cell-wall target via mutations in genes regulating cell-wall synthesis VRSA: Reduced drug binding to target via acquisition of vanA, a plasmid element from Enterococcus spp that encodes a modified D-ala-D-lac precursor

Binding to D-ala-D-ala residues → inhibition of peptidoglycan cell wall synthesis

Decreased drug affinity to target via modified peptidoglycan precursors

Inhibition of enzymes involved in DNA replication, DNA gyrase (topoisomerase II) and topoisomerase IV 1) Alteration of target site via mutations in genes encoding topoisomerase II (gyrA and gyrB) and topoisomerase IV (grlA and grlB) 2) Active drug efflux via overexpression of efflux pumps NorA and NorB

Binding to of the 23S rRNA of 50S ribosomal subunit → protein synthesis inhibition 1) Decreased drug binding via point mutations in the ribosomal binding site 2) Modification of the ribosomal binding site via enzymatic methylation mediated by cfr gene

Binding and inserting into the bacterial cytoplasmic membrane → damage to the cell membrane and to the membrane potential 1) Modification in the peptidoglycan layer via mpfF, an enzyme that incorporates a lysine residue → inhibits binding of daptomycin 2) Changes in phospholipid metabolism via genes encoding cardiolipin synthetases (pgsA, cls) → decreased drug binding

Binding to 16S rRNA of the 30S ribosomal subunit → inhibition of protein synthesis

Enzymatic modification of the drug → decreased drug binding to its target

Beta-lactams with high affinity for PBP2a/PBP2c proteins Resistance to ceftaroline has been reported but the mechanisms are unclear

Sequential binding to 50S ribosomal subunit → inhibition of protein synthesis 1) Modification of ribosomal subunit via acquisition of erm genes encoding methylases → decreased drug binding 2) Enzymatic degradation of the drug via acquisition of acetyltransferases 

C&S, culture and sensitivity; GAS, group-A-streptococcus; ARF, acute rheumatic fever; IL-1, interleukin-1; IL-6, 616 interleukin-6; TNF-alpha, tumor-necrosis-factor-alpha; STSS, streptococcal toxic shock syndrome 617 *ARF can still be prevented if antibiotics for GAS pharyngitis are initiated within 9 days of symptom onset 618 **Rheumatic heart disease is a complication of untreated acute rheumatic fever and is the leading cause of 619 pediatric heart disease worldwide 620 621 J o u r n a l P r e -p r o o f

Antimicrobial resistance in ICUs: an update in the 325 light of the COVID-19 pandemic

Antimicrobial Resistance Threats in the emerging

COVID-19 pandemic: Where do we stand?

The COVID-19 pandemic: a threat to 329 antimicrobial resistance containment

Increased antimicrobial resistance during the COVID-331 19 pandemic

Resistance to Antibiotics: Are We in the Post-Antibiotic Era? Archives of 333

Antibiotic Resistance Threats in the United States

Department of Health and Human Services, CDC

Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of 337 Nations

Antibiotic consumption and link to resistance

Epidemiology of antibiotic resistance in Pseudomonas 471 aeruginosa. Implications for empiric and definitive therapy

Silver LL. Fosfomycin: Mechanism and Resistance. Cold Spring Harb Perspect Med

Epidemiology and Treatment of Multidrug-478

Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections

Geneva: World Health Organization. Licence: CC 481 BY-NC-SA3.OIGO. 482 66

Cutaneous tuberculosis

Executive Summary: Official American Thoracic 487

America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

Drug-resistant 491 tuberculosis: An update on disease burden, diagnosis and treatment

Resistance to trimethoprim-sulfamethoxazole

Phage therapy in the postantibiotic era

Propionibacterium (Cutibacterium) acnes bacteriophage 498 therapy in acne: current evidence and future perspectives

Prospects of phage application in the treatment of acne 502 caused by Propionibacterium acnes

Standard treatment associated with phage therapy versus placebo for diabetic foot 506 ulcers infected by S. aureus (PhagoPied)

ClinicalTrials.gov

Phage therapy for the prevention and treatment of wound infections in burned patients

Figure 1: Outpatient management of skin and soft tissue infections from the Centers for

Abbreviations: I&D, incision and drainage

MRSA, methicillin-resistant staphylococcus aureus; MSSA, methicillin-637 susceptible staphylococcus aureus

SSTIs, skin and soft tissue infections; FDA, Food and Drug Administration

Figure 2: Outpatient management of skin and soft tissue infections from the Infectious Diseases Society of America